Lv5
845 积分 2021-03-22 加入
Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03
2个月前
已完结
Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03
2个月前
已完结
晚期乳腺癌CDK4/6抑制剂一线治疗挑战及进展后策略
3个月前
已完结
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer
3个月前
已完结
Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03
5个月前
已完结
基于卫生经济学评价的我国前列腺癌筛查项目策略优化研究
8个月前
已完结
中国前列腺癌筛查研究报告(白皮书)
8个月前
已完结
恶性肿瘤骨转移及骨相关疾病临床诊疗中国专家共识
8个月前
已完结